Functionally-inactive and immunogenic Tat, Rev and Nef DNA vaccines derived from sub-Saharan subtype C human immunodeficiency virus type 1 consensus sequences. (Q40475569)

From Wikidata

Jump to navigation Jump to search

scientific article

Language	Label	Description	Also known as
English	Functionally-inactive and immunogenic Tat, Rev and Nef DNA vaccines derived from sub-Saharan subtype C human immunodeficiency virus type 1 consensus sequences.	scientific article

Statements

scholarly article

1 reference

Europe PubMed Central

20 September 2017

Functionally-inactive and immunogenic Tat, Rev and Nef DNA vaccines derived from sub-Saharan subtype C human immunodeficiency virus type 1 consensus sequences. (English)

1 reference

Europe PubMed Central

20 September 2017

Sub-Saharan Africa

1 reference

based on heuristic

inferred from title

Thomas J Scriba

1

object named as

Thomas J Scriba

1 reference

Europe PubMed Central

20 September 2017

Susan W Barnett

5

object named as

Susan W Barnett

1 reference

Europe PubMed Central

20 September 2017

Richard H Glashoff

3

object named as

Richard H Glashoff

1 reference

Europe PubMed Central

20 September 2017

author name string

Jan zur Megede

2

1 reference

Europe PubMed Central

20 September 2017

Florette K Treurnicht

4

1 reference

Europe PubMed Central

20 September 2017

Estrelita Janse van Rensburg

6

1 reference

Europe PubMed Central

20 September 2017

language of work or name

0 references

publication date

1 January 2005

1 reference

Europe PubMed Central

20 September 2017

1 reference

Europe PubMed Central

20 September 2017

23

1 reference

Europe PubMed Central

20 September 2017

1158-1169

1 reference

Europe PubMed Central

20 September 2017

9

1 reference

Europe PubMed Central

20 September 2017

Kinetics of Gag-specific cytotoxic T lymphocyte responses during the clinical course of HIV-1 infection: a longitudinal analysis of rapid progressors and long-term asymptomatics

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.08.026

7 January 2021

Persistent high frequency of human immunodeficiency virus-specific cytotoxic T cells in peripheral blood of infected donors

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.08.026

7 January 2021

Cytotoxic-T-cell responses, viral load, and disease progression in early human immunodeficiency virus type 1 infection

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.08.026

7 January 2021

Quantitation of HIV-1-Specific Cytotoxic T Lymphocytes and Plasma Load of Viral RNA

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.08.026

7 January 2021

HIV-1-specific mucosal CD8+ lymphocyte responses in the cervix of HIV-1-resistant prostitutes in Nairobi.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.08.026

7 January 2021

Cytotoxic T cell responses to multiple conserved HIV epitopes in HIV-resistant prostitutes in Nairobi

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.08.026

7 January 2021

HIV-specific cytotoxic T-cells in HIV-exposed but uninfected Gambian women

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.08.026

7 January 2021

Positive selection of HIV-1 cytotoxic T lymphocyte escape variants during primary infection

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.08.026

7 January 2021

Human immunodeficiency virus type 1 Rev- and Tat-specific cytotoxic T lymphocyte frequencies inversely correlate with rapid progression to AIDS.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.08.026

7 January 2021

Rational development of prophylactic HIV vaccines based on structural and regulatory proteins

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.08.026

7 January 2021

Specificity of anti-Nef antibodies produced in mice immunized with DNA encoding the HIV-1 nef gene product.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.08.026

7 January 2021

Control of SHIV-89.6P-infection of cynomolgus monkeys by HIV-1 Tat protein vaccine

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.08.026

7 January 2021

Vaccination with DNA containing tat coding sequences and unmethylated CpG motifs protects cynomolgus monkeys upon infection with simian/human immunodeficiency virus (SHIV89.6P).

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.08.026

7 January 2021

Vaccination with Rev and Tat against AIDS.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.08.026

7 January 2021

The ins and outs of HIV Rev.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.08.026

7 January 2021

The human immunodeficiency virus-1 nef gene product: a positive factor for viral infection and replication in primary lymphocytes and macrophages

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.08.026

7 January 2021

Serine phosphorylation-independent downregulation of cell-surface CD4 by nef

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.08.026

7 January 2021

Endocytosis of major histocompatibility complex class I molecules is induced by the HIV–1 Nef protein

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.08.026

7 January 2021

Recent advances in the understanding of HIV accessory protein function

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.08.026

7 January 2021

Characterization of HIV-1 Tat proteins mutated in the transactivation domain for prophylactic and therapeutic application.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.08.026

7 January 2021

Functional dissection of the HIV-1 Rev trans-activator—Derivation of a trans-dominant repressor of Rev function

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.08.026

7 January 2021

Enhanced T cell engraftment after retroviral delivery of an antiviral gene in HIV-infected individuals

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.08.026

7 January 2021

Expression of a protective gene-prolongs survival of T cells in human immunodeficiency virus-infected patients

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.08.026

7 January 2021

Myristoylation-enhanced binding of the HIV-1 Nef protein to T cell skeletal matrix.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.08.026

7 January 2021

Mutation of a conserved residue (D123) required for oligomerization of human immunodeficiency virus type 1 Nef protein abolishes interaction with human thioesterase and results in impairment of Nef biological functions

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.08.026

7 January 2021

A dileucine motif in HIV-1 Nef acts as an internalization signal for CD4 downregulation and binds the AP-1 clathrin adaptor

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.08.026

7 January 2021

A dileucine motif in HIV-1 Nef is essential for sorting into clathrin-coated pits and for downregulation of CD4

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.08.026

7 January 2021

Genetic analysis of the complete gag and env genes of HIV type 1 subtype C primary isolates from South Africa.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.08.026

7 January 2021

Characterization of the South African HIV type 1 subtype C complete 5' long terminal repeat, nef, and regulatory genes

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.08.026

7 January 2021

Characterization and phylogenetic analysis of South African HIV-1 subtype C accessory genes.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.08.026

7 January 2021

Genotypic and phenotypic analysis of the env gene from South African HIV-1 subtype B and C isolates.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.08.026

7 January 2021

Novel evolutionary analyses of full-length HIV type 1 subtype C molecular clones from Cape Town, South Africa

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.08.026

7 January 2021

A simple method for estimating evolutionary rates of base substitutions through comparative studies of nucleotide sequences

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.08.026

7 January 2021

Increased expression and immunogenicity of sequence-modified human immunodeficiency virus type 1 gag gene

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.08.026

7 January 2021

Eukaryotic mRNAs encoding abundant and scarce proteins are statistically dissimilar in many structural features

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.08.026

7 January 2021

Multiple functional domains of Tat, the trans-activator of HIV-1, defined by mutational analysis

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.08.026

7 January 2021

Elevated levels of mRNA can account for the trans-activation of human immunodeficiency virus

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.08.026

7 January 2021

Steroid-receptor fusion of the human immunodeficiency virus type 1 Rev transactivator: mapping cryptic functions of the arginine-rich motif

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.08.026

7 January 2021

Human immunodeficiency virus type 1 subtype C molecular phylogeny: consensus sequence for an AIDS vaccine design?

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.08.026

7 January 2021

Deletion of N-terminal myristoylation site of HIV Nef abrogates both MHC-1 and CD4 down-regulation

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.08.026

7 January 2021

Development of HIV-1 Nef vaccine components: immunogenicity study of Nef mutants lacking myristoylation and dileucine motif in mice

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.08.026

7 January 2021

Inhibition of human immunodeficiency virus reactivation from latency by a tat transdominant negative mutant.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.08.026

7 January 2021

Inhibition of HIV-1 replication by a Tat transdominant negative mutant in human peripheral blood lymphocytes from healthy donors and HIV-1-infected patients

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.08.026

7 January 2021

Near full-length clones and reference sequences for subtype C isolates of HIV type 1 from three different continents.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.08.026

7 January 2021

Full-length sequence of an ethiopian human immunodeficiency virus type 1 (HIV-1) isolate of genetic subtype C.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.08.026

7 January 2021

Transactivation induced by human T-lymphotropic virus type III (HTLV III) maps to a viral sequence encoding 58 amino acids and lacks tissue specificity

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.08.026

7 January 2021

Interaction of HIV-1 Nef with the cellular dileucine-based sorting pathway is required for CD4 down-regulation and optimal viral infectivity

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.08.026

7 January 2021

Dissociation of the CD4 downregulation and viral infectivity enhancement functions of human immunodeficiency virus type 1 Nef.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.08.026

7 January 2021

Characterization of V3 sequence heterogeneity in subtype C human immunodeficiency virus type 1 isolates from Malawi: underrepresentation of X4 variants.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.08.026

7 January 2021

Virus-specific CD8+ cytotoxic T-lymphocyte activity associated with control of viremia in primary human immunodeficiency virus type 1 infection

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.08.026

7 January 2021

based on heuristic

inferred from DOI database lookup

Association between virus-specific cytotoxic T-lymphocyte and helper responses in human immunodeficiency virus type 1 infection

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.08.026

7 January 2021

based on heuristic

inferred from DOI database lookup

Mutational definition of the human immunodeficiency virus type 1 Rev activation domain.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.08.026

7 January 2021

based on heuristic

inferred from DOI database lookup

Mutational analysis of the conserved cysteine-rich region of the human immunodeficiency virus type 1 Tat protein

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.08.026

7 January 2021

based on heuristic

inferred from DOI database lookup

A comprehensive panel of near-full-length clones and reference sequences for non-subtype B isolates of human immunodeficiency virus type 1.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.08.026

7 January 2021

based on heuristic

inferred from DOI database lookup

A second-site mutation that restores replication of a Tat-defective human immunodeficiency virus

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.08.026

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1016/J.VACCINE.2004.08.026

1 reference

Europe PubMed Central

20 September 2017

1 reference

Europe PubMed Central

20 September 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q40475569&oldid=1984901013"